The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
ELEVATED RED CELL DISTRIBUTION WIDTH TO PLATELET RATIO IS ASSOCIATED WITH LOW GRADE DYSPLASIA IN IBD
TREATMENT OF STAGE IV EARLY-ONSET COLORECTAL CANCER: A COMPARATIVE ANALYSIS
RANDOMIZED CONTROLLED TRIAL ON ORAL ADMINISTRATION OF LACTOBACILLUS CASEI DG FOR 8 WEEKS AFTER ILEOSTOMY CLOSURE (MICROBIOTA AND IMMUNE (MICROENVIRONMENT IN POUCHITIS.-MEP1- NCT03136419).
IMPACT OF END-ILEOSTOMY VERSUS ILEAL POUCH-ANAL ANASTOMOSIS ON GRAFT-SURVIVAL FOLLOWING LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS
IMPACT OF TIME TO SURGERY ON OUTCOMES FOLLOWING LOW ANTERIOR RESECTION FOR RECTAL CANCER
TRENDS IN COST SHARING AND CANCER TREATMENT MODALITY UTILIZATION AMONG COMMERCIALLY INSURED PATIENTS WITH GASTROINTESTINAL CANCER
RCMIX MODEL BASED ON PRE-NEOADJUVANT THERAPY T2WI IMAGING CAN PREDICT THE T-STAGE DOWNSTAGING IN MRI-CT4 STAGE RECTAL CANCER PATIENTS
MESENTERIC LENGTHENING TECHNIQUES FOR ILEOANAL POUCH CONSTRUCTION: WHAT TO DO WHEN THE POUCH WON'T REACH
IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
DOES MESORECTAL FASCIA INVOLVEMENT (MRF) AFFECT THE RESPONSE TO TNT IN LOCALLY ADVANCED RECTAL CANCERS?
ONCOLOGIC OUTCOMES AFTER POUCH EXCISION: IS THERE A DIFFERENCE BETWEEN IBD AND FAP POUCH NEOPLASIA?
IS THERE A ROLE FOR TOTAL NEOADJUVANT TREATMENT IN EARLY-STAGE RECTAL CANCER
METASTASECTOMY FOR STAGE IV COLORECTAL CANCER IS ASSOCIATED WITH IMPROVED SURVIVAL - BUT NOT ALL PATIENTS HAVE ACCESS TO IT
UNRAVELING THE CELLULAR MECHANISMS OF INTESTINAL ANASTOMOTIC HEALING: THE ROLE OF THE SEROSA